Lifecore Biomedical’s Earnings Call Contradictions: Alcon Ramp Timing, Reshoring-FDA Drivers, and 2027 Outlook Clash

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $34.2M for Q2, down 6.2% YOY; $57.4M for six months, down 19.9% YOY
• EPS: Net loss of $0.19 per diluted share for Q2 vs. $0.06 loss per diluted share prior year; $0.61 loss per diluted share for six months vs. $0.48 loss per diluted share prior year
• Gross Margin: Not explicitly provided; gross profit decreased YOY
• Operating Margin: Not explicitly provided; adjusted EBITDA decreased YOY

Guidance:

• Total revenue for 2026 expected to be $120M-$125M.
• Adjusted EBITDA for 2026 expected to be $20.5M-$25M.
• Expects a step-up in CDMO revenues in the back half of the year, including higher aseptic and development revenues.
• Revenue guidance for second half midpoint is ~$65M; adjusted EBITDA ~$13M.
• SG&A, excluding one-time items, expected to be in the $6M quarter range in the back half.
• Expects continued reductions in SG&A and R&D expenses, with cumulative total since late 2024 being $16.2M.

Business Commentary:

Revenue and Demand Outlook:

• Lifecore Biomedical reported revenue of $34.2 million for the second quarter of 2026, a 6.2% decrease compared to the prior year quarter ended May 25, 2025.
• Despite the decrease, the company expects a step-up in CDMO revenues in the back half of the year, with a projected $65 million revenue midpoint for the second half, aligning with their full-year guidance of $120 million-$125 million.
• The decline was primarily due to lower development revenue, a contractual take-or-pay arrangement in the prior year period, and unfavorable manufacturing costs.

Operational and Cost Improvements:

• Gross profit for the quarter was $12.1 million, a $1.9 million decrease compared to the prior year quarter.
• The company achieved five consecutive quarters of period-over-period declines in SG&A and R&D expenses, with a cumulative reduction of $16.2 million since late 2024.
• These improvements were driven by reductions in accounting, consulting, and legal expenses, which contributed to better EBITDA margins.

Pipeline and Business Development Success:

• Lifecore added six new programs to its pipeline in the second quarter, with expectations for commercial revenue in the 2028-2029 timeframe.
• The company's business development efforts have resulted in nine new business wins through June 30 and 13 wins over the last 12 months.
• The success is attributed to a revamped commercial strategy, favorable market dynamics, and increased interest from customers seeking high-quality contract manufacturers.

Liquidity and Financial Health:

• The company ended the second quarter with approximately $38.8 million in liquidity, including cash of $17.2 million and revolving credit availability of $21.6 million.
• This improved liquidity position supports the company's operational improvements and financial stability, enabling it to meet compliance requirements and fund future growth.

Regulatory Environment and Market Position:

• Lifecore successfully completed inspections with regulatory agencies, including the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), which is crucial for entering new markets.
• The company benefited from increased FDA enforcement actions and the regionalization of manufacturing, attracting customers looking for reliable and technically capable contract manufacturers.

Sentiment Analysis:

Overall Tone: Positive

• CEO states: 'We are energized by the success and progress we are making.' 'We now have line of sight to the doubling of the fill finish demand with our largest customer beginning in 2027.' 'We couldn't be more excited about the progress, and certainly the organization is energized by it.' Reaffirmed full-year guidance and expressed optimism about pipeline and market dynamics.

Q&A:

• Question from Matt Hewitt (Craig-Hallum): With the Alcon ramp that’s expected to start next year, does that start on day one, January 2nd? Will you see that inflection, or is that going to ramp over the course of the year?
  Response: Starts early in 2027 with a slightly heavier weighting on the back end of 2027.

• Question from Matt Hewitt (Craig-Hallum): Is the success in new wins a function of reshoring, excess capacity, or special fill-finish capabilities?
  Response: Driven by regionalization of manufacturing and increased FDA enforcement, leading customers to seek high-quality sterile injectable suppliers with strong technical capabilities.

• Question from Paul Knight (KeyBanc Capital Markets): Where are you with the Series A preferred instrument?
  Response: Liquidity is best it's been in years; any payment would require credit agreement approval and would accrue 1% per month interest if not paid by December 28.

• Question from Paul Knight (KeyBanc Capital Markets): What type of fill finish are you seeing in wins?
  Response: Heavily weighted to prefill syringe.

• Question from Paul Knight (KeyBanc Capital Markets): Are you seeing any interest due to onshoring efforts?
  Response: Yes, won opportunities from Europe, Israel, and India.

• Question from Mac Etoch (Stephens): Given some of the timing aspects, was there any change in how HA manufacturing flowed through versus initial expectations?
  Response: HA demand was strong but timing was in line with full-year expectations; CDMO revenue expected to be strong in back half, weighted toward Q4.

• Question from Mac Etoch (Stephens): How have utilization expectations and CapEx evolved given new wins?
  Response: On track for 12% CAGR and >25% EBITDA margins by 2029; expect to utilize ~60% of existing capacity, with headroom for growth; Site 3 optionality will be evaluated.

• Question from Christine Reins (William Blair): Can you quantify the split between Q3 and Q4 for back-half weighting?
  Response: Weighting is due to timing of existing orders in hand, causing a slight back-end bias, but company remains on track for full-year guidance.

• Question from Christine Reins (William Blair): With ample capacity, is there an opportunity to shift free cash flow toward debt reduction?
  Response: Yes, improving free cash flow allows for more debt service in cash; projections show ~60% capacity in 2029, leaving room for growth.

• Question from Michael Petusky (Barrington Research): Did you say SG&A can trend down towards $6M per quarter in the second half?
  Response: Yes, SG&A is expected to trend down to ~$6M per quarter in the second half.

• Question from Michael Petusky (Barrington Research): What is the expected free cash flow for the second half?
  Response: Full-year free cash flow expected to be $7M-$10M, with second half generation following the stronger EBITDA performance.

• Question from Michael Petusky (Barrington Research): What liquidity level is comfortable to run the business if considering paying off preferred holders?
  Response: Dependent on future facts; must retain enough to meet debt compliance and fund growth.

• Question from Michael Petusky (Barrington Research): How will you prepare employee footprint for 2027-2028 growth?
  Response: Little incremental SG&A focus on direct labor and supervision for development/commercialization; confident in adding talent as needed.

• Question from Michael Petusky (Barrington Research): Does success change hurdle rate for new business agreements?
  Response: Will continue to lean heavily on late-stage and commercial site transfers due to de-risked nature, but won't shy away from early-phase programs.

Contradiction Point 1

Timeline and Weighting of Alcon/PharmaCielo Customer Inflection

Contradiction on when the major customer volume increase begins.

Matt Hewitt (Craig-Hallum) - Matt Hewitt (Craig-Hallum)

2026Q2: The ramp starts earlier in 2027, with a slightly heavier weighting on the back end of 2027. - Paul Josephs(CEO)

With the Alcon ramp expected to start next year, will it begin on January 2nd with an immediate inflection, or will it gradually ramp over the course of the year? - Christine Rains (William Blair, on for Max Mock)

2026Q1: Clarity will also come from customer forecasts and the inflection point of more than doubling volumes with the largest customer. - Ryan Lake(CFO)

Contradiction Point 2

Primary Drivers for New Business Wins

Contradiction on whether reshoring or FDA enforcement is the main driver for new wins.

Matt Hewitt (Craig-Hallum) - Matt Hewitt (Craig-Hallum)

2026Q2: The wins are driven by the regionalization of manufacturing and increased FDA enforcement... - Paul Josephs(CEO)

What drives the success in new wins: reshoring, excess capacity, or fill-finish capabilities? - Matthew Hewitt (Craig-Hallum Capital Group)

2026Q1: Reshoring is a 'meaningful' factor, estimated at 'low double digits' of the pipeline. An equally significant factor is the increased FDA enforcement... - Paul Josephs(CEO)

Contradiction Point 3

2027 Revenue Growth Outlook and Specifics

Contradiction on providing specific guidance versus no specific guidance for 2027.

Matt Hewitt (Craig-Hallum) - Matt Hewitt (Craig-Hallum)

2026Q2: The ramp starts earlier in 2027... with a slightly heavier weighting on the back end of 2027. - Paul Josephs(CEO)

Does the Alcon ramp start on January 2nd with an immediate inflection, or will it ramp gradually over the course of the year? - Christine Rains (William Blair, on for Max Mock)

2026Q1: No specific guidance is provided for 2027 yet. Key 2027 milestones... will become clearer later in the year. - Ryan Lake(CFO)

Contradiction Point 4

Revenue and EBITDA Weighting

The expected quarterly split of revenue and EBITDA between the first and second half of the year has changed.

Christine Reins (William Blair) - Christine Reins (William Blair)

2026Q2: The back-half weighting is due to order timing and is more pronounced in Q4 for both revenue and EBITDA. - Ryan Lake(CFO)

Is the back-half revenue weighting specific to Q4 and does it apply to revenue or EBITDA? - Steven Etoch (Stephens Inc.)

2025Q4: Expected split ~mid-40% in H1, ~mid-50% in H2 [for revenue]... ~40% in H1, ~60% in H2, showing continued progression. - Ryan Lake(CFO)

Contradiction Point 5

Timeline for Free Cash Flow Neutrality

Expectation shifts from neutrality in second half 2025 to positive range for full year 2026.

Michael Petusky (Barrington Research) - Michael Petusky (Barrington Research)

2026Q2: Full-year free cash flow is expected to be in the $7 million-$10 million range... - Ryan Lake(CFO)

What free cash flow do you expect in the second half? - Michael Petusky (Barrington Research)

20251107-2025 Q3: ...anticipates a dramatic improvement in free cash flow, expecting to be free cash flow neutral or slightly positive for the second half. - Ryan Lake(CFO)